Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tanya Simuni

Showing results (171-180 of 196) with videos related to

Pageof 20
Sort By:
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2016
Technology in Parkinson's disease: Challenges and opportunitiesAlberto J Espay, Paolo Bonato, Fatta B Nahab, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
Annals of Clinical and Translational Neurology|December 22, 2020
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)Ruth B Schneider, Larsson Omberg, Eric A Macklin, et al.
Science Translational Medicine|August 30, 2023
A blood-based marker of mitochondrial DNA damage in Parkinson's diseaseRui Qi, Esther Sammler, Claudia P Gonzalez-Hunt, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.
Pageof 20

Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
Annals of Clinical and Translational Neurology|December 20, 2018
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohortKenneth Marek, Sohini Chowdhury, Andrew Siderowf, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2016
Technology in Parkinson's disease: Challenges and opportunitiesAlberto J Espay, Paolo Bonato, Fatta B Nahab, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
Annals of Clinical and Translational Neurology|December 22, 2020
Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD)Ruth B Schneider, Larsson Omberg, Eric A Macklin, et al.
Science Translational Medicine|August 30, 2023
A blood-based marker of mitochondrial DNA damage in Parkinson's diseaseRui Qi, Esther Sammler, Claudia P Gonzalez-Hunt, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
The Lancet. Neurology|April 14, 2023
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studyAndrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, et al.
The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.
Pageof 20